US: AKBLF - ALK-Abelló A/S

Rentabilität für sechs Monate: +46.12%

Aktionsplan ALK-Abelló A/S

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen

ALK-Abelló A/S operates as an allergy solutions company in Europe, North America, and internationally. Its product portfolio includes GRAZAX/GRASTEK, RAGWITEK/RAGWIZAX, ACARIZAX/ODACTRA, MITICURE, CEDARCURE, and ITULAZAX/ITULATEK for treatment of allergic rhinitis and allergic asthma. The company offers allergy immunotherapy products in the form of injections, sublingual drops, and tablets for the treatment of various allergies, including grass, ragweed, house dust mite, Japanese cedar, tree, and food.

Weitere Details
It also provides consumer healthcare solution, which include Digital eco-system, a platform which connect and engages with allergy sufferers in the disease journey through tools and e-commerce offerings that supports, guidance and relief, and smoothing the path to allergy immunotherapy treatment. In addition, the company offers diagnostic allergy solutions through testing by skin prick test or blood test; and emergency treatment, such as intra-muscular injection of adrenaline for the treatment of acute life-threatening allergic reactions, including Anaphylaxis. The company has a collaboration with Torii Pharmaceutical Co., Ltd. to develop, market and distribute allergy immunotherapy tablet for the treatment of grass pollen allergy. ALK-Abelló A/S was founded in 1923 and is headquartered in Horsholm, Denmark.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета dkk
Сайт https://www.alk.net
Цена ао 27.03
Preisänderung pro Tag: 0% (27.0328)
Preisänderung pro Woche: +9.89% (24.6)
Preisänderung pro Monat: +24.69% (21.68)
Preisänderung über 3 Monate: +33.17% (20.3)
Preisänderung über sechs Monate: +46.12% (18.5)
Preisänderung pro Jahr: +137.13% (11.4)
Preisänderung über 3 Jahre: -94.45% (487)
Preisänderung über 5 Jahre: -87.8% (221.5)
Preisänderung über 10 Jahre: 0% (27.0328)
Preisänderung seit Jahresbeginn: +137.13% (11.4)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 0 0
P/E 0 0
EV/EBITDA 0 0
Gesamt: 2.5

Effizienz

Name Bedeutung Grad
ROA, % 0 0
ROE, % 0 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 1 10
Gesamt: 1.61

Pflicht

Name Bedeutung Grad
Debt/EBITDA 0 10
Gesamt: 10

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 47.34 6
Rentabilität Ebitda, % 268.55 10
Rentabilität EPS, % -833.33 0
Gesamt: 3.2
Weitere Details

Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Claus Steensen Solje Executive VP, CFO & Member of Management Board 1972 (52 Jahr)
Mr. Søren Daniel Niegel Executive VP of Commercial Operations & Member of Management Board 1971 (53 Jahr)
Dr. Henriette Mersebach Executive VP Research & Development & Member of Management Board 1971 (53 Jahr)
Ms. Katja Barnkob Thalund Project Director of Global CMC Development & Employee-elected Director 1969 (55 Jahre)
Ms. Lise Lund Maerkedahl Project Director of Global Research & Employee-elected Director 1967 (57 Jahre)
Mr. Peter Halling President & CEO 1977 (47 Jahre)
Mr. Per Plotnikof VP of Corporate Communications, Investor Relations & Strategic Planning and Head of IR
Prof. Hendrik Kees Kam Nolte M.D., Ph.D. Senior Vice President of Research & Development - North America and International Markets
Mr. Christian G. Houghton Head of Product Supply
Mr. Peter Sejer Andersen Senior Vice President of Global Research & Drug Discovery

Adresse: Denmark, Horsholm, BOege AllE 6-8 - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.alk.net